Evidence map›Paper›PMID 41764185›Full record

ArticleNature communications2026

Asymmetric synthesis of Heteroatom-bridged [3.2.1]Octane scaffolds via enantioselective β-H elimination reaction.

Chao Fang, Junpeng Ai, Quanpu Wang, Bing Xu, Junliang Zhang, Zhan-Ming Zhang

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chao FangState Key Laboratory of Green Chemical Synthesis and Conversion, Department of Chemistry, Fudan University, Shanghai, China.
Junpeng AiChemical Engineering and Materials Science & Collaborative Innovation Center of Suzhou Nano Science and Technology, Soochow University, Suzhou, China.
Quanpu WangState Key Laboratory of Green Chemical Synthesis and Conversion, Department of Chemistry, Fudan University, Shanghai, China.
Bing XuSchool of Pharmacy, Naval Medical University, Shanghai, China.
Junliang ZhangState Key Laboratory of Green Chemical Synthesis and Conversion, Department of Chemistry, Fudan University, Shanghai, China. junliangzhang@fudan.edu.cn.ORCID http://orcid.org/0000-0002-4636-2846
Zhan-Ming ZhangState Key Laboratory of Green Chemical Synthesis and Conversion, Department of Chemistry, Fudan University, Shanghai, China. zhanmingzhang@fudan.edu.cn.ORCID http://orcid.org/0009-0008-8902-2527

Funding

National Natural Science Foundation of China (National Science Foundation of China) 22031004National Natural Science Foundation of China (National Science Foundation of China) 22501294Science and Technology Commission of Shanghai Municipality (Shanghai Municipal Science and Technology Commission) 23ZR1445600Shanghai Municipal Education Commission 20212308
6 · The paper itself

Abstract

N-bridged [3.2.1]octanes (tropanes) and their related bridged bicyclic systems constitute highly sought-after scaffolds in drug discovery and development. Notably, the enantioselective synthesis of chiral 3-aryltropanes which are compounds widely distributed across bioactive pharmaceutical agents remains underdeveloped. Tropinone is a readily available and cost-effective starting material. By initiating the synthesis from tropinone, it is possible to substantially lower the synthesis costs. Here we describe an enantioselective Pd/Ming-Phos-catalyzed β-H elimination reaction of Tropinone-derived N-arylsulfonylhydrazones and aryl bromides to give chiral tropanes and oxatropanes. Strikingly, this study achieves enantioselective β-H elimination which needs to simultaneously control over both diastereoselectivity during the migratory insertion and enantioselectivity during the β-H elimination. This approach shows broad functional group tolerance, good enantiocontrol as well as easy scale-up. Moreover, the synthetic value is further demonstrated by the enantioselective catalytic total synthesis of drugs for treating Alzheimer's disease and monoamine transporter ligands. Additionally, both the facile elaborations and the preliminary biological activities of the products demonstrate the application potential.

Identifiers

PMID41764185
PMCPMC13066372

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.